Status:
COMPLETED
The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage
Lead Sponsor:
Medstar Health Research Institute
Collaborating Sponsors:
Sequenom Laboratories
Conditions:
Circulating Cell Free Fetal DNA
Intrauterine Fetal Demise
Eligibility:
FEMALE
18+ years
Brief Summary
Women presenting to Washington Hospital Center with fetal loss would be offered participation in the study. The objective is to determine if ccffDNA obtained from maternal blood is present in the sett...
Eligibility Criteria
Inclusion
- Women diagnosed with Intrauterine fetal demised or missed abortion
Exclusion
- Patients diagnosed with threatened abortion with cardiac activity present
- Patients with IUFD who have delivered the fetus (the induction process may already be in process, however, the fetus and placenta must be in situ at the time of blood sampling)
- Patients with known genetic abnormalities or mental retardation as a result of chromosomal abnormalities 13, 18, 21, or sex chromosomes.
- Children under the age of 18
- Patients not fluent in or unable to consent to the study in English
Key Trial Info
Start Date :
May 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01916928
Start Date
May 1 2013
End Date
December 1 2014
Last Update
March 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010